Discussion on NEJM Article NEJMoa2503643

Created using ChatSlide

This presentation provides an insightful overview of Nerandomilast, an oral PDE4B inhibitor with antifibrotic and immunomodulatory properties proven to affect idiopathic pulmonary fibrosis (PF). It delves into the study's background, aiming to halt PF progression and assess its impact on non-idiopathic forms. Conducted as a Phase 3, double-blind, placebo-controlled trial, the study involved 1176 patients on nintedanib. Key findings indicate a significant reduction in FVC decline over 52...